C-3HRQTolerance Bio
thymus therapeutics, immune tolerance, iPSC-derived organoids
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-3HRQ
C-3HRQC-3HRQthymus therapeutics, immune tolerance, iPSC-derived organoids
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Tolerance Bio thymus therapeutics, immune tolerance, iPSC-derived organoids
Tolerance Bio is focused on increasing healthspan by preserving, restoring, and manipulating thymus function. The company describes the thymus as the master regulator of immune tolerance and highlights work on implanted iPSC-derived thymic organoids and targeted thymus therapeutics. Its stated therapeutic direction includes immune-mediated diseases.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Tolerance Bio — Early mechanism · Bottom quartile. Derived deterministically from 2 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic